- On the verge of releasing potential Cannabis-based blockbuster Alzheimer’s treatment
- Company is able to hugely accelerate release of this treatment in recreational cannabis states
- Market potential for drugs to treat and prevent Alzheimer’s is in the billions of dollars
According to information from the Alzheimer’s Association, approximately 47 million people are living with dementia throughout the world—a figure that has been projected to rise to 76 million by 2030. There is still no cure for this devastating disease. However, India Globalization Capital, Inc. (NYSE MKT: IGC) is on the precipice of bringing a potential blockbuster treatment for Alzheimer’s to the market—an event that could happen by early 2018.
Recently, IGC announced it is readying a line of cannabis-based products targeting Alzheimer’s disease based on novel data (http://cnw.fm/0pACN). The company has been engineering genetic cell lines that show the protein Aβ decreases by as much as 40 percent at various concentrations of tetrahydrocannabinol (THC) without neuron damage. (Amyloid beta peptides, or Aβ plaque, buildup in the brain is believed to be the chief cause of Alzheimer’s). This compelling in vitro data shows tremendous promise for treating and even preventing Alzheimer’s.
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer